

William C Dougall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2149059/publications.pdf>

Version: 2024-02-01

18
papers

1,533
citations

566801

15
h-index

940134

16
g-index

20
all docs

20
docs citations

20
times ranked

2519
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>TIGIT</scp> and <scp>CD</scp>96: new checkpoint receptor targets for cancer immunotherapy. <i>Immunological Reviews</i> , 2017, 276, 112-120.	2.8	351
2	TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma. <i>Blood</i> , 2018, 132, 1689-1694.	0.6	198
3	Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 5183-5188.	3.2	171
4	The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. <i>Nature Immunology</i> , 2020, 21, 1205-1218.	7.0	110
5	CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. <i>Journal of Clinical Investigation</i> , 2018, 128, 2613-2625.	3.9	91
6	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. <i>Cancer Immunology Research</i> , 2019, 7, 559-571.	1.6	79
7	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells. <i>Immunity</i> , 2020, 53, 805-823.e15.	6.6	79
8	Roles of the RANKL-RANK axis in antitumour immunity – implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 676-693.	12.5	77
9	Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. <i>Clinical Cancer Research</i> , 2017, 23, 5789-5801.	3.2	70
10	RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. <i>Oncolmmunology</i> , 2018, 7, e1431088.	2.1	67
11	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 3671-3681.	3.2	53
12	An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. <i>Oncolmmunology</i> , 2018, 7, e1480301.	2.1	48
13	Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. <i>Oncolmmunology</i> , 2018, 7, e1445949.	2.1	46
14	CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity. <i>Oncolmmunology</i> , 2018, 7, e1424677.	2.1	44
15	The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells. <i>Immunology and Cell Biology</i> , 2019, 97, 152-164.	1.0	29
16	Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). <i>Trials</i> , 2019, 20, 753.	0.7	20
17	An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21001-e21001.	0.8	0
18	Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS129-TPS129.	0.8	0